$XBI $153.43 (+3.27%) 📈
COVID:
$VRNA (+4.64%) - Verona Pharma Completes Enrollment in Pilot Study of pMDI Ensifentrine in U.S. Patients Hospitalized with COVID-19
PIPELINE:
$ACRX (-6.53%) - AcelRx Announces Year-End 2020 Metrics and Review of 2020 Achievements
$LXRX (+105.36%) - Phase 3 clinical studies can support a new drug application (NDA) submission
$ALKS (+0.82%) - NIDA-Funded Study Evaluating Extended-Release Injectable Naltrexone Plus Bupropion for the Treatment of Methamphetamine Use Disorder Published in New England Journal of Medicine
$BCYC (+28.46%) - Bicycle Therapeutics Announces Pipeline Progress Update
$ETON (+5.68%) - Eton Pharmaceuticals Announces Acquisition of Canadian Rights for ALKINDI® SPRINKLE
$MIRM (-5.24%) - Mirum Pharmaceuticals Announces First Patient Enrolled in Phase 2b VISTAS Clinical Study Evaluating Volixibat in Adult Patients With Primary Sclerosing Cholangitis
$NK (+20.37%) - NantKwest, ImmunityBio Announce Positive Interim Data on Survival Rates in Metastatic Pancreatic Cancer Trials
$ONCT (+11.59%) - Oncternal Therapeutics, Inc. Confirms Lentigen Technology, Inc. to Manufacture Lentiviral Vectors for Its ROR1-targeting CAR-T Cell Therapy Program
$ERYP (+0.27%) - ERYTECH ANNOUNCES FIRST PATIENT ENROLLED IN A PHASE 1 INVESTIGATOR SPONSORED TRIAL OF ERYASPASE IN FIRST-LINE PANCREATIC CANCER
$ORTX (+12.52%) - Orchard Therapeutics Announces OTL-200 Granted Regenerative Medicine Advanced Therapy (RMAT) Designation by FDA for the Treatment of Metachromatic Leukodystrophy (MLD)
$XENE (+1.83%) - Xenon Pharmaceuticals Outlines Key Milestone Opportunities and Planned Leadership Transition in 2021
FINANCIAL:
$PRVB (-6.93%) - Provention Bio Announces Pricing of $100 Million Public Offering of Common Stock
$RDHL (-2.38%) - RedHill Biopharma Announces Closing of $25 Million Bought Deal Offering
Comments